Hesperidin
-
Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio
COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a…
-
Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19
In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
